COST-EFFECTIVENESS OF FRACTURE PREVENTION IN ESTABLISHED OSTEOPOROSIS

被引:67
作者
JONSSON, B
CHRISTIANSEN, C
JOHNELL, O
HEDBRANDT, J
机构
[1] CTR CLIN & BASIC RES,BALLERUP,DENMARK
[2] MALMO GEN HOSP,DEPT ORTHOPED,S-21401 MALMO,SWEDEN
[3] LINKOPING UNIV,SYST ANAL GRP,LINKOPING,SWEDEN
关键词
COST-EFFECTIVENESS; FRACTURE; MODEL; OSTEOPOROSIS; PREVENTION;
D O I
10.1007/BF01623315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study presents the results of a computer simulation model for calculating the cost-effectiveness and cost-utility of treating patients with established osteoporosis in order to reduce the risk of fractures. The results are based on Swedish data for risk of fracture and costs. The treatment intervention modelled is based on treatment of a 62-year-old woman with established osteoporosis. The cost per hip fracture avoided is 350 000 SEK, assuming a 50% reduction in the risk of fracture due to 5 years of treatment. A sensitivity analysis for changes in the cost and effectiveness of treatment, the risk of fracture and the discount rate is performed. The cost per life-year gained and the cost per quality-adjusted life-year (QALY) gained is presented to enable comparison of the cost-effectiveness of treating osteoporosis with that of other health care interventions. A comparison between treating the same woman for osteoporosis and mild hypertension shows a cost per Life-year gained of 220 000 SEK and 128 000 SEK respectively. Cost per QALY gained is very similar for the two interventions:105 000 SEK and 103 000 SEK respectively. This model provides a tool to enable clinicians, administrators and health policy makers to analyze and understand the economic aspects of a major health policy issue.
引用
收藏
页码:136 / 142
页数:7
相关论文
共 50 条
[41]   The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis [J].
Hansheng Ding ;
Nobuo Koinuma ;
Matt Stevenson ;
Michiya Ito ;
Yasutake Monma .
Journal of Bone and Mineral Metabolism, 2008, 26 :34-41
[42]   Cost-effectiveness strategies to treat osteoporosis in elderly women [J].
Pfister, Alfred K. ;
Welch, Christine A. ;
Lester, Melissa D. ;
Emmett, Mary K. ;
Saville, Paul D. ;
Duerring, Shea A. .
SOUTHERN MEDICAL JOURNAL, 2006, 99 (02) :123-131
[43]   Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review [J].
Y. Wan ;
F. Zeng ;
H. Tan ;
Y. Lu ;
Y. Zhang ;
L. Zhao ;
R. You .
Osteoporosis International, 2022, 33 :979-1015
[44]   The cost-effectiveness of alendronate in the management of osteoporosis [J].
Kanis, John A. ;
Adams, Judith ;
Borgstrom, Fred ;
Cooper, Cyrus ;
Jonsson, Bengt ;
Preedy, Danielle ;
Selby, Peter ;
Compston, Juliet .
BONE, 2008, 42 (01) :4-15
[45]   The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis [J].
Borgstrom, F. ;
Strom, O. ;
Coelho, J. ;
Johansson, H. ;
Oden, A. ;
McCloskey, E. ;
Kanis, J. A. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (02) :339-349
[46]   Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis [J].
M. Hiligsmann ;
W. Ben Sedrine ;
O. Bruyère ;
J.-Y. Reginster .
Osteoporosis International, 2013, 24 :2291-2300
[47]   The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis [J].
Ding, Hansheng ;
Koinuma, Nobuo ;
Stevenson, Matt ;
Ito, Michiya ;
Monma, Yasutake .
JOURNAL OF BONE AND MINERAL METABOLISM, 2008, 26 (01) :34-41
[48]   The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis [J].
F. Borgström ;
O. Ström ;
J. Coelho ;
H. Johansson ;
A. Oden ;
E. McCloskey ;
J. A. Kanis .
Osteoporosis International, 2010, 21 :339-349
[49]   Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis [J].
Berto, Patrizia ;
Maggi, Stefania ;
Noale, Marianna ;
Lopatriello, Stefania .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 22 (02) :179-188
[50]   Cost-effectiveness of prevention of coronary disease in Germany [J].
Lauterbach, KW ;
Gerber, A ;
Klever-Deichert, G ;
Stollenwerk, B .
ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 :100-104